TITLE

Hematopoietic stem cell transplantation activity in Europe 1999

AUTHOR(S)
Gratwohl, A; Passweg, J; Baldomero, H; Urbano-Ispizua, A
PUB. DATE
May 2001
SOURCE
Bone Marrow Transplantation;5/1/2001, Vol. 27 Issue 9, p899
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This survey on transplantation of hematopoietic stem cells from blood or bone marrow in Europe, the 10th in a series, reports the numbers of transplants performed in 1999 and concentrates on changes in indications and donor types. Members of the European Group for Blood and Marrow Transplantation and associated teams are invited every year to report their transplant numbers by indication, donor type and stem cell source. In 1999, a total 21 430 transplants were performed by 580 teams in 35 European countries. Of these transplants 18 720 were first transplants, 5879 (31%) allogeneic, 12 841 (69%) autologous; an additional 562 allogeneic and 2148 autologous transplants were re- or multiple transplants. Ninety-five percent of the autologous transplants and 45% of the allogeneic transplants were peripheral blood stem cell transplants. A total of 103, respectively 1.8% of the allogeneic transplants, were cord blood cell transplants. Main indications in 1999 were leukemias with 6289 transplants (34%), 70% thereof allogeneic transplants; lymphomas with 8219 transplants (44%), 92% thereof autologous transplants; solid tumors with 3302 transplants (18%), 99% thereof autologous transplants; nonmalignant disorders with 715 transplants (4%), 85% thereof allogeneic transplants. Absolute numbers of allogeneic transplants continued to increase as in previous years by 10%, in contrast, there was for the first time in 10 years a decrease in autologous transplants, mainly for solid tumors. Reasons therefore are discussed. These data reflect the most recent changes in utilisation and document current status of blood and marrow transplantation in Europe. Bone Marrow Transplantation (2001) 27, 899–916.
ACCESSION #
8888462

 

Related Articles

  • Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Chunduri, S.; Dobogai, L. C.; Peace, D.; Saunthararajah, Y.; Quigley, J.; Chen, Y.-H.; Mahmud, N.; Hurter, E.; Beri, R.; Rondelli, D. // Bone Marrow Transplantation;Jun2008, Vol. 41 Issue 11, p935 

    In this study, we utilized a conditioning regimen with fludarabine and myeloablative dose i.v. BU (12.8 mg/kg) (FluBU) in 36 adult patients (median age: 44 years, range: 18�61) with myeloid or lymphoid malignancies at standard risk (n=10) or high risk of relapse (n=26), who received an...

  • Comorbidity and beyond: pre-transplant clinical assessment. Artz, A. S. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 6, p473 

    Investigates the use of comorbidity scales that provide relative weights to nondisease-related medical conditions as predictors of hematopoietic stem cell transplantation outcomes. Importance of pre-transplant comorbidity assessment; Efficacy of this method compared to single organ comorbidity...

  • Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Alamo, J.; Shahjahan, M.; Lazarus, H. M.; de Lima, M.; Giralt, S. A. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 6, p475 

    Summary:Comorbid conditions have not been studied systematically for impact upon patient outcome in the setting of hematopoietic stem cell transplantation (HSCT). Patients formerly excluded from myeloablative transplant due to comorbid illnesses now receive reduced-intensity conditioning...

  • Prediction of duration and success rate of unrelated hematopoietic stem cell donor searches based on the patient's HLA-DRB1 allele and DRB1-DQB1 haplotype frequencies. Hirv, K.; Bloch, K.; Fischer, M.; Einsiedler, B.; Schrezenmeier, H.; Mytilineos, J. // Bone Marrow Transplantation;Oct2009, Vol. 44 Issue 7, p433 

    Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele...

  • IL-4-producing CD8+ T cells may be an immunological hallmark of chronic GVHD. Nakamura, K.; Amakawa, R.; Takebayashi, M.; Son, Y.; Miyaji, M.; Tajima, K.; Nakai, K.; Ito, T.; Matsumoto, N.; Zen, K.; Kishimoto, Y.; Fukuhara, S. // Bone Marrow Transplantation;Oct2005, Vol. 36 Issue 7, p639 

    Summary:Chronic graft-versus-host disease (cGVHD) occurs in approximately 60–80% of those who survive over 100 days after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the pathophysiology of cGVHD is poorly understood. To gain more insight into the immunological...

  • Biology of human bone marrow stem cells. Bonnet, D. // Clinical & Experimental Medicine;Sep2003, Vol. 3 Issue 3, p140 

    The bone marrow is constituted of two separate and distinct stem cells. The hematopoietic stem cells (HSC) are responsible for the production and maintenance of all the mature blood cells. The mesenchymal stem cells constituted the bone marrow stroma. In this report we review our current...

  • Immunotherapy: New directions for tumour therapy. Buckland, Jenny // Nature Reviews Immunology;Jul2003, Vol. 3 Issue 7, p513 

    Presents the result of a study on the treatment of tumors by using a bone marrow transplantation-based strategy in which hematopoietic stem cells are transduced with genes. Development of dendritic cell-based anti-tumor vaccines; Methodology of the study; Details of the success of the strategy.

  • 23. Selected Aspects.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS237 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S237–S240. DOI: 10.1038/sj/bmt/1703492

  • Hematopoietic stem cell transplantation for autoimmune diseases in developing countries: current status and future prospectives. Voltarelli, J C; Ouyang, J // Bone Marrow Transplantation;Aug2003 Supplement 1, Vol. 32 Issue 1, pS69 

    Summary:In this paper we present preliminary results of hematopoietic stem cell transplantation for autoimmune diseases in Brazil and China. Chinese experience transplanting lupus is significant and the Brazilian experience with several autoimmune diseases is growing. We discuss peculiar...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics